Functional role of the endocannabinoid system in emotional homeostasis;Implicación funcional del sistema cannabinoide endógeno en la homeostasis emocional

Revista de Neurologia

Volumn 48, Issue 1, 2009, Pages 20-26

  Marco, E M ^a   Viveros Hernando, M Paz ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Animal models; Anxiety; Endogenous cannabinoid system; Stress

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABIS; ENDOCANNABINOID;

AMYGDALOID NUCLEUS; ANXIETY DISORDER; BRAIN CORTEX; EMOTION; HEREDITY; HIPPOCAMPUS; HOMEOSTASIS; NEUROBIOLOGY; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

EID: 61849162748     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4801.2008218     Document Type: Review

References (83)

1. Cano-Vindel A, Miguel-Tobal JJ, González H, Iruarrizaga- Díez I. El afrontamiento de la ansiedad en las drogodependencias. Anales de Psicología 1994; 10: 145-156.
2. Millan MJ. The neurobiology and control of anxious states. Prog Neurobiol 2003; 70: 83-244.
3. Dannon PN, Lowengrub K, Amiaz R, Grunhaus L, Kotler M. Comorbid cannabis use and panic disorder: short term and long term follow-up study. Hum Psychopharmacol 2004; 19: 97-101.
4. Patton GC, Coffey C, Carlin JB, Degenhardt L, Lynskey M, Hall W. Cannabis use and mental health in young people: cohort study. BMJ 2002; 325: 1195-8.
5. Tournier M, Sorbara F, Gindre C, Swendsen JD, Verdoux H. Cannabis use and anxiety in daily life: a naturalistic investigation in a non-clinical population. Psychiatry Res 2003; 118: 1-8.
6. Mackie K. Distribution of cannabinoid receptors in the central and peripheral nervous system. In Pertwee RG, ed. Cannabinoids handbook of experimental pharmacology. Berlin: Springer; 2005. p. 299-323.
7. Onaivi ES, Ishiguro H, Gong JP, Patel S, Perchuk A, Meozzi PA, et al. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci 2006; 1074: 514-36.
8. Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 2006; 147 Suppl 1: S163-71.
9. Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 2003; 83: 1017-66.
10. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 2004; 47 (Suppl 1): 345-58.
11. Marsicano G, Lutz B. Neuromodulatory functions of the endocannabinoid system. J Endocrinol Invest 2006; 29: 27-46.
12. Viveros MP, Marco EM, Llorente R, López-Gallardo M. Endocannabinoid system and synaptic plasticity: implications for emotional responses. Neural Plast 2007: 52908.
13. Moreira FA, Lutz B. The endocannabinoid system: emotion, learning and addiction. Addict Biol 2008; 13: 196-212.
14. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006; 58: 389-462.
15. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006; 27: 73-100.
16. Viveros MP. Cannabinoides y procesos de memoria y aprendizaje. In Sociedad Española de Investigación sobre Cannabinoides, eds. Guía básica sobre los cannabinoides. Madrid: SEIC; 2002. p. 93-100.
17. Viveros MP, Marco EM, File SE. Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 2005; 81: 331-42.
18. Gorzalka BB, Hill MN, Hillard CJ. Regulation of endocannabinoid signalling by stress: implications for stress-related affective disorders. Neurosci Biobehav Rev 2008; 32: 1152-60.
19. Genn RF, Tucci S, Marco EM, Viveros MP, File SE. Unconditioned and conditioned anxiogenic effects of the cannabinoid receptor agonist cp 55,940 in the social interaction test. Pharmacol Biochem Behav 2004; 77: 567-573.
20. Haller J, Matyas F, Soproni K, Varga B, Barsy B, Nemeth B, et al. Correlated species differences in the effects of cannabinoid ligands on anxiety and on gabaergic and glutamatergic synaptic transmission. Eur J Neurosci 2007; 25: 2445-56.
21. Marco EM, Pérez-Álvarez L, Borcel E, Rubio M, Guaza C, Ambrosio E, et al. Involvement of 5-HT1A receptors in behavioural effects of the cannabinoid receptor agonist cp 55,940 in male rats. Behav Pharmacol 2004; 15: 21-27.
22. Rodríguez de Fonseca F, Rubio P, Menzaghi F, Merlo-Pich E, Rivier J, Koob GF, et al. Corticotropin-releasing factor (CRF) antagonist [dphe12,nle21,38,c alpha meleu37]CRFf attenuates the acute actions of the highly potent cannabinoid receptor agonist hu-210 on defensive-withdrawal behavior in rats. J Pharmacol Exp Ther 1996; 276: 56-64.
23. Valjent E, Mitchell JM, Besson MJ, Caboche J, Maldonado R. Behavioural and biochemical evidence for interactions between delta 9-tetrahydrocannabinol and nicotine. Br J Pharmacol 2002; 135: 564-78.
24. Viveros MP, Marco EM, Llorente R, Lamota L. The role of the hippocampus in mediating emotional responses to nicotine and cannabinoids: a possible neural substrate for functional interactions. Behav Pharmacol 2007; 18: 375-89.
25. File SE. Behavioural detection of anxiolytic action. In Elliot JM, Heal DJ, Marsden CA, eds. Experimental approaches to anxiety and depression. New York: Wiley; 1992. p. 25-44.
26. Kantor S, Anheuer ZE, Bagdy G. High social anxiety and low aggression in fawn-hooded rats. Physiol Behav 2000; 71: 551-7.
27. Guimaraes FS, Chiaretti TM, Graeff FG, Zuardi AW. Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology (Berl) 1990; 100: 558-9.
28. Guimaraes FS, de Aguiar JC, Mechoulam R, Breuer A. Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze. Gen Pharmacol 1994; 25: 161-4.
29. Onaivi ES, Green MR, Martin BR. Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exp Ther 1990; 253: 1002-9.
30. Bortolato M, Mangieri RA, Fu J, Kim JH, Arguello O, Duranti A, et al. Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry 2007; 62: 1103-10.
31. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A, et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 2003; 9: 76-81.
32. Rutkowska M, Jamontt J, Gliniak H. Effects of cannabinoids on the anxiety-like response in mice. Pharmacol Rep 2006; 58: 200-6.
33. Manzanares J, Corchero J, Fuentes JA. Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of Δ9-tetrahydrocannabinol in rats. Brain Res 1999; 839: 173-9.
34. Martín-Calderón JL, Muñoz RM, Villanua MA, Del Arco I, Moreno JL, De Fonseca FR, et al. Characterization of the acute endocrine actions of (-)-11-hydroxy-delta8-tetrahydrocannabinol-dimethylheptyl (HU-210), a potent synthetic cannabinoid in rats. Eur J Pharmacol 1998; 344: 77-86.
35. Rodríguez de Fonseca FR, Villanua MA, Muñoz RM, San Martín-Clark O, Navarro M. Differential effects of chronic treatment with either dopamine D1 or D2 receptor agonists on the acute neuroendocrine actions of the highly potent synthetic cannabinoid hu-210 in male rats. Neuroendocrinology 1995; 61: 714-21.
36. Romero EM, Fernández B, Sagredo O, Gómez N, Uriguen L, Guaza C, et al. Antinociceptive, behavioural and neuroendocrine effects of CP 55,940 in young rats. Brain Res Dev Brain Res 2002; 136: 85-92.
37. Weidenfeld J, Feldman S, Mechoulam R. Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat. Neuroendocrinology 1994; 59: 110-2.
38. Berrendero F, Maldonado R. Involvement of the opioid system in the anxiolytic-like effects induced by delta(9)-tetrahydrocannabinol. Psychopharmacology (Berl) 2002; 163: 111-7.
39. Marín S, Marco E, Biscaia M, Fernández B, Rubio M, Guaza C, et al. Involvement of the kappa-opioid receptor in the anxiogenic-like effect of CP 55,940 in male rats. Pharmacol Biochem Behav 2003; 74: 649-56.
40. Braida D, Limonta V, Malabarba L, Zani A, Sala M. 5-HT1A receptors are involved in the anxiolytic effect of delta9-tetrahydrocannabinol and am 404, the anandamide transport inhibitor, in Sprague-Dawley rats. Eur J Pharmacol 2007; 555: 156-63.
41. File SE, González LE, Andrews N. Comparative study of pre- and postsynaptic 5-HT1A receptor modulation of anxiety in two ethological animal tests. J Neurosci 1996; 16: 4810-5.
42. Sakaue M, Ago Y, Sowa C, Koyama Y, Baba A, Matsuda T. The 5-HT1A receptor agonist MKC-242 increases the exploratory activity of mice in the elevated plus-maze. Eur J Pharmacol 2003; 458: 141-4.
43. Gaetani S, Cuomo V, Piomelli D. Anandamide hydrolysis: a new target for anti-anxiety drugs? Trends Mol Med 2003; 9: 474-8.
44. Roohbakhsh A, Moghaddam AH, Massoudi R, Zarrindast MR. Role of dorsal hippocampal cannabinoid receptors and nitric oxide in anxiety like behaviours in rats using the elevated plus-maze test. Clin Exp Pharmacol Physiol 2007; 34: 223-9.
45. Begg M, Pacher P, Batkai S, Osei-Hyiaman D, Offertaler L, Mo FM, et al. Evidence for novel cannabinoid receptors. Pharmacol Ther 2005; 106: 133-45.
46. Mackie K, Stella N. Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J 2006; 8: E298-306.
47. Kasckow JW, Mulchahey JJ, Geracioti TDJ. Effects of the vanilloid agonist olvanil and antagonist capsazepine on rat behaviors. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 291-5.
48. Marsch R, Foeller E, Rammes G, Bunck M, Kossl M, Holsboer F, et al. Reduced anxiety, conditioned fear, and hippocampal long-term potentiation in transient receptor potential vanilloid type 1 receptor-deficient mice. J Neurosci 2007; 27: 832-9.
49. Cristino L, De Petrocellis L, Pryce G, Baker D, Guglielmotti V, Di Marzo V. Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience 2006; 139: 1405-15.
50. Haller J, Bakos N, Szirmay M, Ledent C, Freund TF. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci 2002; 16: 1395-8.
51. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl) 2002; 159: 379-87.
52. Urigüen L, Perez-Rial S, Ledent C, Palomo T, Manzanares J. Impaired action of anxiolytic drugs in mice deficient in cannabinoid cb1 receptors. Neuropharmacology 2004; 46: 966-73.
53. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002; 418: 530-4.
54. Haller J, Varga B, Ledent C, Barna I, Freund TF: Context-dependent effects of CB1 cannabinoid gene disruption on anxiety-like and social behaviour in mice. Eur J Neurosci 2004; 19: 1906-12.
55. Arévalo C, De Miguel R, Hernández-Tristán R. Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters. Pharmacol Biochem Behav 2001; 70: 123-31.
56. McGregor IS, Dastur FN, McLellan RA, Brown RE. Cannabinoid modulation of rat pup ultrasonic vocalizations. Eur J Pharmacol 1996; 313: 43-9.
57. Navarro M, Hernández E, Muñoz RM, Del Arco I, Villanua MA, Carrera MR, et al. Acute administration of the cb1 cannabinoid receptor antagonist SR141716A induces anxiety-like responses in the rat. Neuroreport 1997; 8: 491-6.
58. Rodgers RJ, Haller J, Halasz J, Mikics E. 'One-trial sensitization' to the anxiolytic-like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus-maze. Eur J Neurosci 2003; 17: 1279-86.
59. Patel S, Roelke CT, Rademacher DJ, Cullinan WE, Hillard CJ. Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 2004; 145: 5431-8.
60. Wade MR, Degroot A, Nomikos GG. Cannabinoid cb1 receptor antagonism modulates plasma corticosterone in rodents. Eur J Pharmacol 2006; 551: 162-7.
61. Barna I, Zelena D, Arszovszki AC, Ledent C. The role of endogenous cannabinoids in the hypothalamo-pituitary-adrenal axis regulation: in vivo and in vitro studies in CB1 receptor knockout mice. Life Sci 2004; 75: 2959-70.
62. Di S, Malcher-Lopes R, Halmos KC, Tasker JG. Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism. J Neurosci 2003; 23: 4850-7.
63. Cota D. The role of the endocannabinoid system in the regulation of hypothalamic-pituitary-adrenal axis activity. J Neuroendocrinol 2008; 20: 35-8.
64. Hill MN, Patel S, Carrier EJ, Rademacher DJ, Ormerod BK, Hillard CJ, et al. Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology 2005; 30: 508-15.
65. Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M, et al. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA 2005; 102: 18620-5. Erratum in: Proc Natl Acad Sci U S A 2005; 103: 12465.
66. Hill MN, Gorzalka BB. Increased sensitivity to restraint stress and novelty-induced emotionality following long-term, high dose cannabinoid exposure. Psychoneuroendocrinology 2006; 31: 526-36.
67. Patel S, Roelke CT, Rademacher DJ, Hillard CJ. Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling. Eur J Neurosci 2005; 21: 1057-69.
68. Rademacher DJ, Hillard CJ. Interactions between endocannabinoids and stress-induced decreased sensitivity to natural reward. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 633-41.
69. Hill MN, Kambo JS, Sun JC, Gorzalka BB, Galea LA. Endocannabinoids modulate stress-induced suppression of hippocampal cell proliferation and activation of defensive behaviours. Eur J Neurosci 2006; 24: 1845-9.
70. Williamson EM, Evans FJ. Cannabinoids in clinical practice. Drugs 2000; 60: 1303-14.
71. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl) 1982; 76: 245-50.
72. Mechoulam R, Peters M, Murillo-Rodríguez E, Hanus LO. Cannabidiol -recent advances. Chem Biodivers 2007; 4: 1678-92.
73. Moreira FA, Aguiar DC, Guimaraes FS. Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1466-71.
74. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001; 134: 845-52.
75. Braida D, Pegorini S, Arcidiacono MV, Consalez GG, Croci L, Sala M. Post-ischemic treatment with cannabidiol prevents electroencephalographic flattening, hyperlocomotion and neuronal injury in gerbils. Neurosci Lett 2003; 346: 61-4.
76. Hamelink C, Hampson A, Wink DA, Eiden LE, Eskay RL. Comparison of cannabidiol, antioxidants, and diuretics in reversing binge ethanol-induced neurotoxicity. J Pharmacol Exp Ther 2005; 314: 780-8.
77. Cravatt BF, Lichtman AH. Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. Curr Opin Chem Biol 2003; 7: 469.75.
78. Maccarrone M. Fatty acid amide hydrolase: a potential target for next generation therapeutics. Curr Pharm Des 2006; 12: 759-72.
79. Patel S, Hillard CJ. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 2006; 318: 304-11.
80. Giuliani D, Ferrari F, Ottani A. The cannabinoid agonist HU 210 modifies rat behavioural responses to novelty and stress. Pharmacol Res 2000; 41: 47-53.
81. Micale V, Cristino L, Tamburella A, Petrosino S, Leggio GM, Drago F, et al. Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology 2009; 34: 593-606.
82. Maccarrone M, Valverde O, Barbaccia ML, Castañé A, Maldonado R, Ledent C, et al. Age-related changes of anandamide metabolism in CB1 cannabinoid receptor knockout mice: correlation with behaviour. Eur J Neurosci 2002; 15: 1178-86.
83. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999; 283: 401-4.